Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients

NCT00610194 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT00610194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00610194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase 1, Dose-Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of RDEA119, A MEK Inhibitor, in Advanced Cancer Patients
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
November 28, 2007
Completion date
August 1, 2012
Enrollment
69 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer